Nervous System & Special Senses

Malignant spinal cord compression: recognition and emergency management

Clinical Overview and When to Suspect Malignant Spinal Cord Compression

— Occurs in ~3–5% of all cancer patients; up to 10% in metastatic disease

— Most common primaries: breast, lung, prostate, multiple myeloma, renal cell, lymphoma

— Thoracic spine ~60%, lumbosacral ~25%, cervical ~15%; ~30% have multilevel disease (mandates whole-spine imaging)

— MSCC is the presenting feature of cancer in ~20% of cases — do not require a known malignancy to suspect it

— New or progressive back pain in any patient >50 or with known cancer, especially nocturnal, recumbent-worsened, band-like, or thoracic pain

— Pain preceding neurologic deficits by a median of ~7 weeks — this is the therapeutic window

— Any cancer patient with new leg weakness, gait change, saddle anesthesia, urinary retention, or bowel incontinence

— Unexplained falls or "legs giving out" in older adults with weight loss or constitutional symptoms

Board pearl: In a Step 3 vignette, "thoracic back pain, worse lying flat, in a smoker or woman with a breast lump" = order urgent whole-spine MRI with contrast and start IV dexamethasone before the scan returns. Do not wait for imaging to begin steroids if suspicion is high and deficits are present.

Definition: Malignant spinal cord compression (MSCC) is compression of the cord or cauda equina by epidural tumor, vertebral metastasis with retropulsed bone, or pathologic fracture — a true oncologic emergency where minutes-to-hours of delay translate into permanent paraplegia, sensory loss, and sphincter dysfunction.

Epidemiology:

When to suspect in the ED:

Pathophysiology pearl: Epidural venous plexus obstruction → vasogenic cord edema → ischemia. Edema is steroid-responsive, which is why early dexamethasone changes outcomes.

Prognostic anchor: The single best predictor of post-treatment ambulation is ambulatory status at diagnosis — 80–100% of ambulatory patients walk after treatment vs <20% of paraplegic patients.

Presentation Patterns and Key History

— Precedes neurologic deficits by weeks; worse at night, recumbent, or with Valsalva (cough, sneeze, straining) — distinguishes from mechanical/degenerative pain which improves with rest

— Localized (vertebral periosteal stretch), radicular (nerve root compression, dermatomal band), or funicular (referred, non-dermatomal, often mid-thoracic crossing)

— Thoracic band-like or "girdle" pain is classic

— Symmetric or asymmetric leg weakness, proximal > distal

— Patients describe "heavy legs," tripping, inability to climb stairs

— Cervical lesions → quadriparesis; thoracic → paraparesis with preserved arms

— Ascending numbness/paresthesias from feet, sensory level on trunk (highly localizing)

— Saddle anesthesia → cauda equina/conus

— Urinary retention with overflow incontinence (post-void residual >100 mL is a red flag)

— Bowel incontinence, decreased anal tone, erectile dysfunction

— Once autonomic signs appear, recovery probability drops sharply

— Known malignancy, stage, treatments, last imaging

— Smoking, hemoptysis, breast/testicular mass, PSA history, weight loss, night sweats

— Onset and tempo of deficits (hours vs days vs weeks) — rapid progression = worse prognosis and faster intervention

— Steroid use, anticoagulation, prior spine surgery/radiation

Key distinction: Mechanical low back pain improves with recumbency and worsens with activity; MSCC pain worsens with recumbency and at night because venous engorgement increases epidural pressure. This single historical pivot should trigger MRI in any at-risk patient.

Step 3 management: In the ED, document time of symptom onset, ambulatory status, last void, and continence — these drive triage urgency, set the prognostic baseline, and become the medico-legal anchor if deficits progress.

Back pain (95%) — the cardinal symptom:

Motor weakness (60–85%):

Sensory disturbance (40–80%):

Autonomic dysfunction (late, ominous):

Key history to extract rapidly:

Physical Exam Findings and Functional Assessment

— Focal vertebral tenderness to percussion over a spinous process is highly suggestive of bony metastasis or pathologic fracture

— Inspect for kyphosis, gibbus deformity, prior surgical scars, radiation tattoos

— Grade strength 0–5 in all major groups; document hip flexion, knee extension/flexion, ankle dorsi/plantar flexion explicitly

— Upper motor neuron pattern below the lesion (cord): spasticity, hyperreflexia, upgoing Babinski, clonus — may be initially flaccid in spinal shock

— Lower motor neuron pattern (cauda equina): areflexia, flaccid weakness, atrophy

— Map a sensory level with pinprick/temperature on the trunk — nipples = T4, xiphoid = T6, umbilicus = T10, inguinal = L1

— Test saddle sensation (S2–S4) in every suspected case — perineum, perianal, posterior thigh

— Hyperreflexia below lesion, anal wink and bulbocavernosus reflex for sacral integrity

— Beevor sign (umbilicus deviates upward on sit-up) → T10 lesion

— Lhermitte sign (electric shock down spine with neck flexion) → cervical cord involvement

— Post-void bladder scan in every patient — PVR >100–200 mL suggests neurogenic bladder

— Digital rectal exam: resting and squeeze tone, sensation

— Observe gait if safe; tandem walk; Romberg

CCS pearl: On a CCS case, sequential orders should read: "neurologic exam, rectal exam, bladder scan, pain assessment" within the first 10 simulated minutes — the simulator credits early, systematic localization. Re-examine every 4–6 hours until definitive treatment because deterioration mandates escalation.

Spine inspection and palpation:

Motor exam:

Sensory exam:

Reflexes and special signs:

Autonomic/functional:

Document ambulatory status: independent, with assist, non-ambulatory — this is the single most important prognostic variable.

Diagnostic Workup — Initial Labs and Imaging

— Whole-spine MRI with and without gadolinium is the test of choice — sensitivity ~93%, specificity ~97%

— Image the entire spine, not just the symptomatic level — ~30% have synchronous lesions at non-contiguous sites that alter the radiation field

— T1, T2, STIR, and post-contrast sequences; STIR best detects marrow edema/early metastasis

— Target time to MRI: within 24 hours of suspicion, immediately if deficits are progressing

— CT myelography is the next best — useful for pacemakers, certain implants, or unstable patients in centers without immediate MRI

— Plain CT spine: detects vertebral lysis/fracture, retropulsion, but misses epidural soft tissue — do not rely on alone

— Plain radiographs: low sensitivity (~60%); useful only as adjunct for alignment/stability

— CBC, CMP (calcium for hypercalcemia of malignancy, renal/hepatic function before contrast and chemo), LDH, uric acid (tumor burden)

— PSA in men, SPEP/UPEP and serum free light chains if myeloma suspected (especially older patients with anemia, renal failure, hypercalcemia)

— Coagulation panel and type & screen if surgery anticipated

— Pregnancy test in reproductive-age women (impacts steroid/RT decisions)

— CT chest/abdomen/pelvis with contrast to identify primary if unknown

— Bone scan or PET-CT for staging once stable

— If lytic skull lesions or hypercalcemia → bone marrow biopsy planning for myeloma

Board pearl: A patient with new MSCC and no known cancer needs a biopsy of the most accessible lesion (often a vertebral or accessible visceral metastasis) before definitive non-surgical therapy when feasible — but do not delay steroids or emergent decompression for a tissue diagnosis if neurologic function is at stake.

Imaging — MRI is the gold standard:

When MRI is contraindicated or unavailable:

Labs to obtain in the ED:

Other initial studies:

Diagnostic Workup — Advanced and Confirmatory Studies

— Required when primary is unknown — guides systemic therapy and radiosensitivity decisions

— CT-guided percutaneous vertebral or paraspinal biopsy is first-line; preferred over surgical biopsy when patient is non-operative

— If decompressive surgery is planned, intraoperative biopsy at the time of decompression is efficient

— Avoid biopsy of presumed renal cell or thyroid mets without embolization plan — highly vascular

— Highly radiosensitive: lymphoma, multiple myeloma, seminoma, small cell lung cancer → often RT alone, frequently with excellent recovery

— Moderately radiosensitive: breast, prostate, ovarian

— Radioresistant: renal cell, melanoma, sarcoma, non-small cell lung, GI adenocarcinomas → favor surgical decompression + post-op RT or SBRT

— Six domains: location, pain, bone lesion type, alignment, vertebral body collapse, posterolateral involvement

— 0–6 stable, 7–12 indeterminate, 13–18 unstable — score ≥7 mandates surgical consultation

— Tokuhashi, Tomita, or modified Bauer scores estimate survival and inform whether aggressive surgery is appropriate

— Expected survival >3 months favors surgical decompression per landmark Patchell trial (NEJM 2005): surgery + RT > RT alone for ambulation preservation and continence

Key distinction: Radiosensitive tumor + neurologically stable patient → RT alone is reasonable. Single-level compression + retropulsed bone + expected survival >3 months + radioresistant tumor → surgery first, then RT (Patchell paradigm). Step 3 commonly tests this branch point — recognize that radioresistance plus mechanical instability tips toward surgery.

Tissue diagnosis:

Radiosensitivity assessment (guides RT vs surgery):

Spinal stability assessment — SINS (Spinal Instability Neoplastic Score):

Prognostic scoring for surgical candidacy:

Additional staging: PET-CT, MRI brain if symptoms, tumor markers per primary, molecular profiling on biopsy specimen.

Risk Stratification and Management Algorithm

— Suspicion raised → start IV dexamethasone immediately (do not wait for MRI)

— STAT whole-spine MRI ordered

— Spine flat precautions / log-roll until stability assessed

— Consult radiation oncology AND neurosurgery/spine surgery simultaneously

— Pain control, bladder catheterization if retention, VTE prophylaxis (mechanical until decisions made)

— Single-level compression + good performance status (ECOG 0–2) + expected survival >3 months + radioresistant or unstable spine → surgical decompression and stabilization within 24–48 hours, followed by post-op RT (Patchell trial: 84% vs 57% ambulatory)

— Multilevel disease, radiosensitive tumor (lymphoma, myeloma, SCLC, germ cell), or poor surgical candidate → urgent conventional EBRT (typically 30 Gy/10 fx or 20 Gy/5 fx; single 8 Gy fraction for short prognosis)

— Oligometastatic, radioresistant tumor without instability → stereotactic body radiotherapy (SBRT) — increasingly first-line at experienced centers

— Paraplegic >24–48 h with no sacral sparing → poor recovery potential; palliative RT and comfort focus

Step 3 management: The exam-correct sequence is almost always: (1) IV dexamethasone, (2) urgent MRI whole spine, (3) simultaneous rad-onc and neurosurgery consults, (4) definitive therapy within 24 h. Choosing "obtain MRI before steroids" when deficits are present is the wrong answer — steroids are given empirically because the cost of delay is permanent paralysis.

The first 4 hours — parallel processing:

After MRI confirms MSCC — branch points:

Cauda equina syndrome: Surgical emergency — decompression ideally within 24–48 hours of symptom onset to preserve sphincter function

NOMS framework (memory aid): Neurologic grade, Oncologic (radiosensitivity), Mechanical stability, Systemic disease/comorbidities — integrates all four axes for decision-making.

Pharmacotherapy — Dexamethasone and Adjuncts

— Loading dose: 10 mg IV bolus (some protocols use 16 mg or even 96 mg for severe deficits — high-dose data are mixed; 10 mg load is the standard board answer)

— Maintenance: 4 mg IV/PO every 6 hours (16 mg/day) until definitive treatment begins, then taper over 2 weeks

— Mechanism: reduces vasogenic edema, decreases vascular permeability, may have direct lymphocytotoxic effect (relevant in lymphoma)

— Caveat: If lymphoma is in the differential and tissue diagnosis has not been obtained, steroids can obscure the histology — coordinate urgent biopsy first only if neurologic status permits a brief delay; otherwise treat and biopsy after

— Hyperglycemia (monitor glucose, especially in diabetics; insulin sliding scale)

— GI bleeding → PPI prophylaxis

— Insomnia, mood lability, psychosis

— Opportunistic infection with prolonged use — consider PJP prophylaxis if course will exceed 4 weeks at ≥20 mg prednisone equivalent

— Proximal myopathy, osteoporosis, adrenal suppression on taper

— Multimodal: scheduled acetaminophen + opioids (morphine, oxycodone, hydromorphone) titrated to effect

— NSAIDs can help bone pain but caution with renal disease, thrombocytopenia, GI risk on steroids

— Neuropathic adjuncts: gabapentin or pregabalin for radicular pain

— Avoid benzodiazepines in elderly (fall risk, delirium)

— Zoledronic acid 4 mg IV q4 weeks or denosumab 120 mg SC q4 weeks — reduce skeletal-related events

— Check dental status first (osteonecrosis of the jaw risk)

— Correct hypocalcemia and vitamin D before initiating

Board pearl: Dexamethasone 10 mg IV load, then 4 mg q6h is the canonical regimen. Add PPI + glucose monitoring + VTE prophylaxis as the standard supportive bundle.

Dexamethasone — cornerstone empirical therapy:

Steroid side effects to anticipate and pre-empt:

Pain control:

Bone-targeted therapy (started after definitive control):

VTE prophylaxis: LMWH (enoxaparin 40 mg SC daily) — cancer + immobility = very high risk; hold pre-op per surgical team.

Procedures — Surgery, Radiation, and Stabilization

— Landmark 2005 NEJM RCT: direct decompressive surgery + RT vs RT alone in single-level MSCC

— Surgery group: 84% ambulatory post-treatment vs 57%; median 122 vs 13 days of retained ambulation; less steroid and opioid use

— Indications: single-level compression, radioresistant tumor, spinal instability (SINS ≥7), retropulsed bone fragment, paraplegia <48 h, recurrence after prior RT, or need for tissue diagnosis

— Contraindications: multilevel disease, expected survival <3 months, prohibitive surgical risk, complete paraplegia >48 h with no sacral sparing

— Posterior laminectomy with instrumented fusion — most common

— Anterior corpectomy with cage reconstruction for vertebral body destruction

— Separation surgery + post-op SBRT — minimal debulking to create a safe RT margin; favored for radioresistant tumors

— Conventional external beam RT (cEBRT): 30 Gy in 10 fx (standard), 20 Gy in 5 fx (shorter prognosis), or single 8 Gy fraction for very limited survival/palliation

— Stereotactic body RT (SBRT): high-dose, conformal; preferred for radioresistant tumors, oligometastatic disease, re-irradiation, and post-separation surgery

— Begin RT within 24 hours of diagnosis when chosen as primary modality

— For painful pathologic compression fracture without epidural extension or instability — augments vertebral body with cement

— Not a treatment for cord compression itself; adjunctive for pain after definitive therapy

CCS pearl: Order "neurosurgery consult, radiation oncology consult, MRI whole spine with contrast" in parallel within the first hour. The simulator rewards simultaneous consultation rather than sequential — mirroring real multidisciplinary care.

Surgical decompression — Patchell paradigm:

Surgical options:

Radiation therapy:

Vertebroplasty/kyphoplasty:

Embolization: Pre-operative for renal cell, thyroid, hepatocellular mets to reduce intraoperative blood loss.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of MSCC from prostate, breast, lung, and myeloma

— Functional status (ECOG, Karnofsky) and frailty drive treatment choice more than chronologic age

— Surgical candidacy: assess with comprehensive geriatric assessment when time permits; consider less invasive approaches (separation surgery, percutaneous instrumentation) over major open decompression

— Higher delirium risk on steroids and opioids — use lowest effective doses, scheduled acetaminophen first, avoid anticholinergics and benzodiazepines

— Fall and pressure injury risk during prolonged bed rest — early PT, pressure-relieving mattress

— Gadolinium: Avoid group I agents at eGFR <30 (nephrogenic systemic fibrosis risk); newer group II macrocyclic agents (gadobutrol, gadoteridol) are considered safe at low eGFR but still used cautiously

— Iodinated contrast for CT myelography: hydrate; hold metformin around contrast if eGFR <30

— Zoledronic acid contraindicated at CrCl <30; denosumab is preferred in CKD (but watch hypocalcemia — supplement calcium/vitamin D aggressively)

— Adjust opioid dosing: avoid morphine (active metabolites accumulate) → use hydromorphone or fentanyl; avoid meperidine

— Gabapentin/pregabalin require renal dose adjustment

— Dexamethasone metabolism slowed — monitor for cumulative steroid effects

— Acetaminophen ceiling 2 g/day in cirrhosis; avoid NSAIDs (variceal bleed, hepatorenal syndrome)

— Coagulopathy from liver disease increases surgical bleeding — correct with vitamin K, FFP, or platelets pre-op

— Adjust opioid doses downward; fentanyl preferred (no active metabolites)

— IV normal saline 200–300 mL/hr, calcitonin 4 IU/kg SC q12h for rapid effect, zoledronic acid for sustained control (or denosumab if renal impairment)

Board pearl: In an elderly patient with eGFR 25, MSCC, and known breast cancer, the right bone-targeted agent is denosumab, not zoledronic acid — and monitor calcium closely, since hypocalcemia can be severe.

Elderly patients (≥75):

Renal impairment:

Hepatic impairment:

Hypercalcemia of malignancy (common comorbidity, especially myeloma, breast, squamous lung):

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Rare but described — gestational breast cancer, lymphoma, melanoma

— MRI without gadolinium is the imaging modality of choice in any trimester (gadolinium crosses placenta — avoid if possible, especially first trimester)

— Dexamethasone crosses placenta and is generally safe; in fact used for fetal lung maturity — continue at therapeutic doses

— Radiation therapy: shield the gravid uterus; risk depends on gestational age and field — multidisciplinary discussion with maternal-fetal medicine, rad-onc, and oncology

— Surgical decompression is feasible with appropriate positioning (left lateral tilt after 20 weeks) and fetal monitoring

— Delivery timing: if near term, expedite delivery (often C-section) to enable definitive maternal therapy

— Different tumor spectrum: Ewing sarcoma, neuroblastoma, lymphoma, rhabdomyosarcoma, germ cell tumors, primary CNS tumors

— Neuroblastoma classically causes "dumbbell" extension through neural foramina with cord compression in infants

— Dexamethasone dosing weight-based (0.25–0.5 mg/kg load, then maintenance); chemotherapy often first-line for highly chemosensitive pediatric tumors (lymphoma, Ewing, germ cell)

— Avoid RT to growing spine when possible — causes growth arrest, scoliosis, secondary malignancies

— Engage pediatric oncology and pediatric neurosurgery immediately

— Cord tolerance limits (~45–50 Gy cumulative) restrict re-irradiation

— SBRT or surgery become preferred

— Reverse for surgery: vitamin K + 4-factor PCC for warfarin; idarucizumab for dabigatran; andexanet alfa or PCC for apixaban/rivaroxaban

— Resume cautiously post-op given high VTE risk

Step 3 management: A pregnant patient with new MSCC gets non-contrast MRI + IV dexamethasone immediately; defer gadolinium and radiation planning to a multidisciplinary discussion the same day — do not withhold steroids over pregnancy concerns.

Pregnancy:

Pediatrics:

Patients with prior spinal radiation:

Patients on anticoagulation:

Immunocompromised / transplant: infection mimics (epidural abscess, tuberculous Pott disease) must be excluded — see differentials chunk.

Complications and Adverse Outcomes

— Permanent paraplegia or tetraplegia if treatment delayed beyond 24–48 h of complete deficits

— Neurogenic bladder and bowel — chronic catheterization, recurrent UTIs, bowel programs

— Sexual dysfunction — frequently underdiscussed; ask explicitly at follow-up

— Chronic neuropathic pain below the level of injury — often refractory

— Autonomic dysreflexia in lesions above T6 — life-threatening hypertension triggered by bladder distension, bowel impaction, or pressure sores

— Surgical: wound infection, dehiscence (especially after RT), CSF leak, hardware failure, hematoma with cord compression, deep vein thrombosis, pulmonary embolism

— Radiation: acute radiation dermatitis, esophagitis (cervico-thoracic fields), myelopathy (rare with appropriate planning), fatigue, marrow suppression with extensive fields

— Steroid: hyperglycemia, GI bleed, osteoporosis, myopathy, psychiatric effects, opportunistic infection (PJP, candida, reactivation TB/strongyloides)

— Bisphosphonate/denosumab: osteonecrosis of the jaw, atypical femur fracture, severe hypocalcemia (denosumab >> zoledronic acid)

— VTE (incidence up to 30% without prophylaxis), pneumonia, pressure ulcers (sacrum, heels), muscle deconditioning, contractures

— Constipation from opioids, immobility, and autonomic dysfunction → ileus

— Acute adjustment disorder, depression, anxiety; up to 40% develop clinically significant depressive symptoms

— Caregiver burden — particularly when patients lose ambulation

— In-field RT recurrence ~10–20%; re-treatment options include SBRT or surgery

— New levels of compression in ~10–15% — surveillance imaging guided by symptoms

Key distinction: Autonomic dysreflexia (sudden severe HTN, headache, flushing above lesion, pallor below) in a high cord lesion is a hypertensive emergency — sit the patient up, find and remove the trigger (bladder, bowel, skin), and use short-acting antihypertensives (nitrates, nifedipine) only if BP remains dangerously high. Step 3 loves this pattern in rehab/post-discharge stems.

Neurologic complications:

Treatment-related complications:

Systemic complications of immobility:

Psychosocial:

Recurrence:

When to Escalate — ICU, Consults, and Triage

— Neurosurgery or orthopedic spine surgery — for decompression/stabilization candidacy

— Radiation oncology — for urgent RT planning, often same day

— Medical oncology — for systemic therapy decisions and tissue diagnosis coordination

— Interventional radiology — for image-guided biopsy if primary unknown

— High cervical lesion (C5 and above) with respiratory compromise — diaphragm (C3–C5) involvement; monitor negative inspiratory force and vital capacity, intubate before crisis

— Spinal shock with hemodynamic instability (hypotension, bradycardia from loss of sympathetic tone, especially T6 and above) — fluids, vasopressors (norepinephrine), atropine for bradycardia

— Post-operative high cervical or extensive thoracic decompression with hardware

— Severe electrolyte disturbances (hypercalcemic crisis, tumor lysis after starting chemo for lymphoma)

— Confirmed MSCC undergoing RT, with stable neurologic exam and adequate pain control

— Post-op patients beyond the immediate critical window

— Only if MRI excludes MSCC and an alternative diagnosis is established with safe outpatient follow-up

— Any new neurologic deficit or unexplained back pain in a cancer patient = admit

— Centers without 24/7 MRI, neurosurgery, and radiation oncology should transfer urgently rather than delay

— Document neurologic exam at transfer; ensure dexamethasone is given before transport

— Air vs ground transport based on distance and stability

— Address upfront — many patients with advanced cancer benefit from early palliative care consultation alongside aggressive treatment

— Document whether patient would want intubation, CPR, surgery if neurologic recovery is unlikely

CCS pearl: On a CCS case, "transfer to ICU" is the right order if respiratory mechanics deteriorate (FVC <15 mL/kg or NIF less negative than −20 cm H₂O) in a cervical lesion — preempt rather than react.

Immediate consults (within 1 hour of suspicion):

ICU admission criteria:

Inpatient ward criteria:

Discharge from ED rarely appropriate:

Transfer to higher level of care:

Code status and goals of care:

Key Differentials — Same-Category (Spinal/Compressive) Causes

— Fever + back pain + neurologic deficit is the classic triad (present in <15%, so absence does not rule out)

— Risk factors: IV drug use, diabetes, indwelling catheters, recent spinal procedure, bacteremia, immunosuppression

— Elevated ESR/CRP nearly universal; blood cultures positive in ~60%

— MRI with contrast shows rim-enhancing collection; S. aureus most common organism

— Treatment: surgical drainage + IV antibiotics (vancomycin + ceftriaxone empirically)

— Sudden severe back pain + rapidly progressive deficits in patients on anticoagulation, after spinal anesthesia/lumbar puncture, or coagulopathic

— MRI shows hyperintense collection; emergent surgical evacuation

— Reverse anticoagulation immediately

— Subacute back pain, fever, elevated inflammatory markers; Brucella, TB (Pott disease), Staph aureus

— Pott disease classically thoracolumbar with gibbus deformity and paraspinal/psoas abscess

— Intramedullary (ependymoma, astrocytoma) — central cord syndrome pattern

— Intradural extramedullary (meningioma, schwannoma, neurofibroma) — slow growing

— Differentiated from MSCC by location on MRI and clinical tempo

— Massive central disc herniation can cause cauda equina; usually younger patients with acute injury or chronic degenerative disease

— No bony destruction, no systemic illness

— Slowly progressive over years; gait spasticity, hand clumsiness in cervical stenosis

— Older patients without malignancy; MRI shows multilevel degenerative changes

— Postmenopausal women, chronic steroid users; usually no epidural extension unless severe retropulsion

Key distinction: Fever + spinal pain + IV drug use → epidural abscess until proven otherwise; anticoagulant + sudden pain + rapid deficit → epidural hematoma. Both are surgical emergencies that mimic MSCC clinically — the MRI is the unifying test.

Spinal epidural abscess:

Spinal epidural hematoma:

Vertebral osteomyelitis / discitis:

Primary spinal tumors:

Disc herniation with cord compression:

Degenerative spinal stenosis with myelopathy:

Spontaneous vertebral compression fracture (osteoporotic):

Key Differentials — Other-Category Causes of Acute Weakness

— Ascending symmetric flaccid weakness with areflexia, often post-infectious (Campylobacter, CMV, EBV, recent vaccination)

— No sensory level, no bowel/bladder involvement early, no spinal pain typically

— LP: albuminocytologic dissociation (high protein, normal WBC); nerve conduction shows demyelination

— Treatment: IVIG or plasmapheresis; monitor respiratory function

— Acute/subacute bilateral motor, sensory, and autonomic dysfunction with clear sensory level — can mimic MSCC exactly

— MRI shows intramedullary T2 hyperintensity spanning ≥3 vertebral segments (longitudinally extensive in NMO spectrum disorder)

— Causes: MS, NMO, post-infectious, post-vaccination, paraneoplastic

— Treatment: high-dose IV methylprednisolone 1 g daily × 5 days, plasmapheresis if refractory

— Hyperacute (minutes-hours) painless or pain-preceded paraplegia in an anterior spinal artery distribution (motor + spinothalamic loss, dorsal columns spared)

— Risk: aortic surgery/dissection, atherosclerosis, hypotension, vasculitis

— MRI may be normal early; DWI shows restricted diffusion

— Younger patients, prior episodes, MRI with periventricular/juxtacortical/infratentorial lesions plus cord lesions <2 segments

— Inconsistent exam (Hoover sign positive), preserved reflexes, normal imaging — diagnosis of exclusion

— Severe hypokalemia, hypophosphatemia, hypermagnesemia — diffuse weakness, not focal

— Hypercalcemia of malignancy → weakness, confusion, constipation — coexists with MSCC frequently

— Myasthenia gravis crisis, Lambert-Eaton (paraneoplastic with small cell lung cancer) — fluctuating weakness, ocular/bulbar involvement, no sensory loss

Board pearl: Acute paraplegia with dissociated sensory loss (preserved vibration/proprioception) and history of aortic surgery = anterior spinal artery infarction, not MSCC. Imaging differentiates — but the clinical pattern alone should redirect your workup.

Guillain-Barré syndrome (GBS):

Transverse myelitis:

Spinal cord infarction:

Multiple sclerosis flare:

Conversion disorder/functional weakness:

Metabolic mimics:

Neuromuscular junction:

Secondary Prevention and Long-Term Plan

— Hormone therapy for prostate (ADT ± androgen receptor inhibitors) and breast (endocrine therapy ± CDK4/6 inhibitors)

— Chemotherapy for lymphoma, myeloma, small cell lung, germ cell — often highly effective

— Targeted therapy: EGFR/ALK inhibitors in NSCLC, HER2-targeted in breast, etc.

— Immunotherapy: melanoma, renal cell, NSCLC — consider continuation/initiation

— Zoledronic acid 4 mg IV q4 weeks or denosumab 120 mg SC q4 weeks indefinitely while on systemic therapy

— Reduces skeletal-related events by ~30–40%

— Dental clearance before initiation; supplement calcium 1000–1200 mg + vitamin D 800–1000 IU daily

— Monitor renal function (zoledronic acid) and calcium (denosumab)

— Dexamethasone taper over 2 weeks (e.g., 4 mg q6h → q8h → q12h → daily → off)

— PPI while on steroids

— VTE prophylaxis — typically LMWH for 4 weeks post-op, then reassess; cancer patients often need extended thromboprophylaxis

— Bowel regimen (senna + docusate) — opioid- and immobility-induced constipation

— Analgesics with clear taper plan and naloxone co-prescription per opioid stewardship

— Antiepileptic (gabapentin/pregabalin) if neuropathic pain

— Bone-modifying agent and supplements as above

— Per oncology protocol — typically every 2–3 months initially with cross-sectional imaging

— Repeat spine MRI for any new pain or neurologic symptom — low threshold

— Document goals of care; many patients are in the last year of life

— Palliative care co-management improves quality of life and may extend survival

Step 3 management: At discharge, the four columns of orders are: (1) steroid taper + PPI, (2) VTE prophylaxis, (3) pain regimen with bowel program, (4) bone-modifying agent + Ca/Vit D. Missing any one is a common test trap.

Tumor-directed systemic therapy (initiated after acute stabilization):

Bone-modifying agents (long-term):

Discharge medication checklist:

Imaging surveillance:

Advance care planning:

Follow-Up, Monitoring, and Rehabilitation

— Radiation oncology: 2–4 weeks post-RT, then every 2–3 months

— Neurosurgery: 2 weeks post-op for wound check, 6 weeks for imaging if instrumented

— Medical oncology: within 1–2 weeks of discharge to initiate/resume systemic therapy

— Primary care: within 1–2 weeks for medication reconciliation, glucose monitoring, mood screening

— Physiatry / rehab medicine: early — ideally inpatient rehab for non-ambulatory or partially recovered patients

— Neurologic exam at each visit — strength, sensation, reflexes, gait, sphincter function

— Glucose: fingersticks during steroid taper; HbA1c at 3 months

— Bone density (DEXA) at 1 year for long-term steroid users

— Calcium, phosphate, renal function with each bisphosphonate/denosumab dose

— Pain scores and opioid morphine milligram equivalents — taper as tolerated

— Acute inpatient rehab (3 hours/day therapy) for patients with reasonable prognosis and rehab potential

— Subacute rehab / SNF for patients needing slower progression

— Goals: ambulation, transfers, ADLs, bladder/bowel management, equipment training (wheelchair, walker, AFO)

— Spasticity management: baclofen, tizanidine, botulinum toxin for focal spasticity

— Bladder management: intermittent catheterization preferred over indwelling Foley; anticholinergics for detrusor overactivity (oxybutynin, but watch cognition in elderly)

— Bowel program: scheduled stimulation, fiber, stool softeners, senna; manage neurogenic bowel proactively

— Screen for depression (PHQ-9) and anxiety at every visit

— Sexual health discussions — explicitly invite questions

— Caregiver support, social work, home health, durable medical equipment

— Driving evaluation if motor function impaired

— Vocational and disability considerations

CCS pearl: Ordering "physical therapy, occupational therapy, social work consultation, palliative care consultation" early in the case — even in the ED — is rewarded; rehab planning is a Step 3 hallmark.

Follow-up cadence:

Monitoring parameters:

Rehabilitation:

Counseling and psychosocial:

Ethical, Legal, and Patient Safety Considerations

— MSCC management often requires same-day surgical or radiation decisions with imperfect information

— Capacity assessment is critical — pain, opioids, steroids, and acute stress can impair decision-making; document capacity explicitly

— When capacity is lacking and no advance directive exists, identify surrogate decision-maker per state hierarchy (typically spouse → adult children → parents → siblings)

— In life-or-limb emergencies with no surrogate reachable, implied consent applies — but document the inability to obtain consent and the urgency

— Many MSCC patients have limited prognosis — discuss what aggressive treatment can and cannot achieve: preservation of function is realistic; cure typically is not

— Avoid surgical heroics in patients with poor prognosis (<3 months) who would not benefit functionally — this is both ethical and evidence-based (Patchell criteria)

— Document DNR/DNI status, code status, and post-op intubation preferences before surgery

— Spine precautions and log-roll until stability documented — falls or unsupported transfers can precipitate complete cord injury

— Diagnostic delay is the leading source of malpractice claims in MSCC — failure to obtain MRI in a cancer patient with new back pain

— Transition-of-care risk: patients discharged on steroid tapers must have clear written instructions, glucose monitoring, and PCP follow-up arranged — abrupt steroid discontinuation can cause adrenal crisis

— Medication reconciliation at every transition — discharge med lists for MSCC patients are long (steroid, PPI, opioid, anticoagulant, bone agent, neuropathic agent, laxative) and error-prone

— VTE prophylaxis omission is a never-event for immobilized cancer patients

— Disparities in MSCC outcomes correlate with access to MRI, specialty referral, and post-acute rehab — advocate for transfer when local resources are insufficient

— Insurance prior authorization should never delay emergency RT or surgery — document medical necessity clearly

— Newly non-ambulatory patients require disability paperwork (FMLA, state disability) and often qualify for expedited Social Security disability under compassionate allowances for metastatic cancer

Board pearl: "Failure to image" is the Step 3 ethics-flavored stem for MSCC. Any cancer patient with new or progressive back pain — even without deficits — gets an MRI on the same encounter.

Informed consent in time-pressured emergencies:

Goals-of-care conversations:

Patient safety pearls:

Health equity considerations:

Mandatory reporting and disability:

High-Yield Associations and Rapid-Fire Facts

Key distinction: Thoracic = MSCC's favorite location; cervical = think respiratory compromise + autonomic dysreflexia risk; lumbar = cauda equina pattern. Location-specific syndromes drive different downstream concerns.

Most common primary cancers causing MSCC: breast, lung, prostate, multiple myeloma, renal cell, lymphoma — together >80% of cases

Most common site: thoracic spine (~60%) — anatomically narrowest canal-to-cord ratio

MSCC is the presenting feature of cancer in ~20% — do not require a known cancer history

Pain precedes neurologic deficits by a median of ~7 weeks — the therapeutic window

Whole-spine MRI is mandatory — 30% have multilevel disease

Patchell trial (2005): surgery + RT > RT alone for ambulation in single-level MSCC with expected survival >3 months

Dexamethasone: 10 mg IV load, then 4 mg IV/PO q6h

Most radiosensitive tumors: lymphoma, myeloma, seminoma, small cell lung cancer

Most radioresistant: renal cell, melanoma, sarcoma — favor surgery

SINS ≥7: indeterminate or unstable spine → surgical consult

Best prognostic indicator: ambulatory status at time of treatment initiation

Cauda equina hallmarks: saddle anesthesia, urinary retention, fecal incontinence, decreased anal tone, areflexia — surgical emergency within 24–48 h

Conus medullaris (T12–L1) lesions: mixed UMN/LMN, early bladder/bowel

Beevor sign (umbilicus deviates up on sit-up) = T10 lesion

Lhermitte sign = cervical cord lesion

Sensory level landmarks: T4 nipple, T6 xiphoid, T10 umbilicus, L1 inguinal

Bone-modifying agent in CKD: denosumab (zoledronic acid contraindicated at CrCl <30)

Vertebroplasty/kyphoplasty: for painful compression fracture without cord compression

Most common organism in epidural abscess (mimic): S. aureus

Anterior spinal artery infarction: motor + spinothalamic loss, dorsal columns spared

Autonomic dysreflexia: lesions T6 or above; treat by removing trigger first

Tokuhashi/Tomita scores: estimate survival to guide surgical candidacy

NOMS framework: Neurologic, Oncologic, Mechanical, Systemic

Board Question Stem Patterns

Step 3 management: When the question asks "next best step," the answer ladder is almost always dexamethasone → MRI → multidisciplinary consults → definitive therapy within 24 h. Choose the earliest action not yet performed.

Stem 1 — Classic presentation: 62-year-old man with known prostate cancer presents with 3 weeks of mid-back pain worse at night, now with bilateral leg weakness and urinary retention. PVR 400 mL. Next step? → IV dexamethasone followed by urgent whole-spine MRI, then simultaneous neurosurgery and rad-onc consults.

Stem 2 — Patchell decision: Patient with single-level T6 compression from renal cell carcinoma, ambulatory with assistance, ECOG 1, life expectancy ~12 months, SINS 9. Best management? → Surgical decompression + stabilization followed by post-operative radiation (radioresistant tumor, unstable spine, good performance status — surgery wins over RT alone).

Stem 3 — Radiosensitive tumor: Newly diagnosed diffuse large B-cell lymphoma with multilevel epidural disease and paraparesis. Next step? → Dexamethasone + urgent radiation therapy ± chemotherapy (highly radiosensitive, multilevel — RT/chemo preferred over surgery). Coordinate tissue diagnosis before extended steroids if feasible.

Stem 4 — Mimic: IV drug user with fever, back pain, leg weakness, WBC 18k, ESR 95. Next step? → MRI with contrast → spinal epidural abscess → surgical drainage + vancomycin + ceftriaxone.

Stem 5 — Cauda equina: Young man with massive disc herniation, saddle anesthesia, urinary retention. Next step? → Emergent MRI lumbosacral spine and surgical decompression within 24–48 h.

Stem 6 — Anticoagulation pitfall: Patient on warfarin with INR 4.5 develops sudden severe back pain and rapid paraplegia after a fall. Next step? → MRI → epidural hematoma → reverse with vitamin K + 4-factor PCC, emergent surgical evacuation.

Stem 7 — Post-discharge complication: Paraplegic patient with T4 lesion develops sudden BP 220/120, severe headache, facial flushing. Next step? → Autonomic dysreflexia — sit patient upright, check bladder (drain if distended) and bowel, treat HTN with nitrates or nifedipine only if persistent.

Stem 8 — Diagnostic delay ethics: Cancer patient discharged from ED with "muscle strain" returns 2 weeks later paraplegic. Tested concept: failure to obtain MRI in any cancer patient with new back pain is the cardinal error; document a low-threshold imaging strategy.

Stem 9 — Pediatric: Toddler with retro-orbital ecchymoses, abdominal mass, and leg weakness → neuroblastoma with dumbbell cord extension.

Stem 10 — Renal impairment: MSCC patient with eGFR 22 needs bone-modifying therapy → denosumab, not zoledronic acid; supplement calcium/vitamin D.

One-Line Recap

Malignant spinal cord compression is an oncologic emergency in which any cancer patient with new or progressive back pain — especially nocturnal, thoracic, or with any neurologic, sensory, or sphincter change — receives immediate IV dexamethasone, urgent whole-spine MRI, and simultaneous neurosurgery and radiation oncology consultation, with definitive therapy delivered within 24 hours, because ambulatory status at the time of treatment is the strongest predictor of long-term function.

Board pearl: The single most tested concept across Step 3 MSCC vignettes is the time-critical sequence: steroids first, MRI urgently, consults in parallel, definitive treatment within 24 hours — and never let pregnancy, renal failure, anticoagulation, or pending tissue diagnosis delay empiric dexamethasone when neurologic function is at stake.

Recognize early: Back pain precedes deficits by weeks — the window closes once paraplegia is established. Cancer patient + new back pain = MRI, every time.

Treat in parallel, not in series: Dexamethasone 10 mg IV load → 4 mg q6h before MRI returns; whole-spine MRI (not just symptomatic level); neurosurgery and rad-onc consulted simultaneously.

Choose modality by NOMS: Surgery + RT for single-level, radioresistant, unstable, good-prognosis disease (Patchell); RT alone for radiosensitive (lymphoma, myeloma, SCLC, germ cell), multilevel, or poor-prognosis disease; SBRT for radioresistant oligometastatic or re-irradiation scenarios.

Don't forget the bundle: VTE prophylaxis, PPI with steroids, bowel regimen, bone-modifying agent (denosumab if CKD), neuropathic pain control, early rehab, palliative care co-management, and a written steroid taper with PCP follow-up to prevent adrenal crisis and readmission.